Epigenomics AG

EANS-News: Epigenomics AG
Epigenomics AG: Dr. Uwe Staub Appointed to the Executive Board

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Board of Directors (Appointments and Changes)

Berlin, Germany, and U.S.A. (euro adhoc) - Epigenomics AG (Frankfurt Prime
Standard: ECX), the German-American cancer molecular diagnostics company, today
announced that Dr. Uwe Staub, Chief Operating Officer (COO) of the Company, has
been appointed to the Executive Board, effective April 1, 2013. He will join the
board as a second member next to Dr. Thomas Taapken, acting CEO and CFO of
Epigenomics.  

Uwe Staub joined Epigenomics in November 2008 as Senior Vice President for
Product Development and was promoted to COO in September 2012, when his duties
were expanded to now encompass R&D, Medical and Regulatory Affairs, Customer
Support and Manufacturing. He joined the Company with 14 years experience in the
IVD industry in different positions in R&D and QA/RA at Abbott Diagnostics,
Digene and Qiagen. He holds a Ph.D. in biochemistry from the University of
Würzburg, Germany.

On his appointment Uwe Staub commented: "During recent months the Epigenomics
team has achieved extremely important milestones for the future of the Company.
I am honored by the appointment and look forward to help guide the Company
through the next phases of its development."

"I welcome Uwe as a new member of the Executive Board. The developments in the
Company over the last months have been very encouraging and exciting. I am
extremely pleased to work with Uwe and the entire Epigenomics team in order to
achieve our shared vision of developing Epigenomics into a commercial success
story," added Thomas Taapken, acting CEO and CFO.

Heino von Prondzynski, Chairman of the Supervisory Board, said: "Dr. Staub has
been instrumental in the successful development of Epigenomics' products. Under
his responsibility, the Company has made significant progress towards regulatory
approval of Epi proColon® in the US for this convenient blood-based colorectal
cancer screening assay. Given his accomplishments and experience we are
convinced he is the ideal candidate to further strengthen our Executive Board."
-Ends-

Contact Epigenomics AG
Antje Zeise
Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel +49 (0) 30 24345 386 
{ir@epigenomics.com}[HYPERLINK: mailto:ir@epigenomics.com]
{www.epigenomics.com}[HYPERLINK: http://www.epigenomics.com/]

For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway
Rockville, Maryland 20850
{pr@epigenomics.com}[HYPERLINK: mailto:pr@epigenomics.com]

About Epigenomics

Epigenomics ({www.epigenomics.com}[HYPERLINK: http://www.epigenomics.com]) is a
molecular diagnostics company developing and commercializing a pipeline of
proprietary products for cancer. The Company's products enable doctors to
diagnose cancer earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based test for
the early detection of colorectal cancer, which is currently marketed in Europe
and is in development for the U.S.A. The Company's technology and products have
been validated through partnerships with leading diagnostic companies and
testing laboratories. Epigenomics is an international company with operations in
Europe and the U.S.A.

Epigenomics' legal disclaimers.

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States of America.
The analytical and clinical performance characteristics of any product based on
this technology which may be sold at some future time in the U.S.A. have not
been established.


Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: